Refine your search
Collections
Co-Authors
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Shinde, N. V.
- Diabetes Macroangiopathy - A Review
Abstract Views :239 |
PDF Views:2
Authors
Affiliations
1 Department of Pharmacology, Seth Govind Raghunath Sable College of Pharmacy, Saswad, Taluka: Purandar, Pune 412301, IN
2 Seth Govind Raghunath Sable College of Pharmacy, Saswad, Taluka: Purandar, Pune 412301, IN
1 Department of Pharmacology, Seth Govind Raghunath Sable College of Pharmacy, Saswad, Taluka: Purandar, Pune 412301, IN
2 Seth Govind Raghunath Sable College of Pharmacy, Saswad, Taluka: Purandar, Pune 412301, IN
Source
Research Journal of Pharmacology and Pharmacodynamics, Vol 1, No 2 (2009), Pagination: 45-49Abstract
Diabetes mellitus, a metabolic disorder characterised by high levels of blood glucose, is associated with several vascular complications. Although insulin treatment, oral medications, dietary regulations and exercise can delay the development of diabetic microangiopathy, the development of macroangiopathy cannot be prevented solely by glycaemic control. However, diabetic-macroangiopathy refers mainly to an accelerated form of atherosclerosis. This in turn affects both the coronary and cerebral vasculature, thus increasing the risk of myocardial infarction, angina pectoris and cerebrovascular accidents. Diabetes mellitus in humans and animal models of diabetes are associated with impaired endothelium-dependent relaxation i.e. endothelial dysfunction. Endothelial dysfunction, a surrogate marker for the development of diabetic macroangiopathy.Keywords
Diabetes Mellitus, Endothelial Dysfunction, Hyperglycemia, Oxidative Stress.
References
- The Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986
- Barar, F.S.K. Essentials of Pharmacotherapeutics, S.Chand publication, 2003; 3rd ed: pp 340-346.
- Harsh Mohan. Text book of Pathophysiology, Diabetes complications Jaypee brother publishers Ltd.1998; 3rd ed: 972-978.
- Antonio Ceriello. Oxidative stress and diabetes associated complications, Endocrine practice 2006; 12: 60-61.
- Ulvi Bayraktutan. Free Radicals, Diabetes and Endothelial Dysfunction, Department of Medicine, Institute of Clinical Science Block B, UK,1-15.
- Brownlee M. The pathobiology of diabetic complications. A unifying mechanism. Diabetes 2005; 54: 1615-25.
- UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ 1998; 317: 703-13.
- Rossing P. The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 2005; 48:143944.
- Gaziano, J.M. Global Burden of cardiovascular disease, In Braunwald E, Ipes D.P and Libby P, Heart disease a textbook of cardiovascular medicine, 1-17.
- Nathan, M.N, Singer, D.E. The epidemiology of cardiovascular disease in type 2 diabetes mellitus:How sweet it is...or is it? Lancet, 4-9.
- Stamler. J, Vacaro. O, Neaton. J. For the Multiple Risk Factor Intervention Trial Research group,Diabetes other risk factors and 12th year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial,434- 444.
- Turner R.C,The U.K.Prospective study: A review, C35-38.
- Feener,E.P,and King,G.L,Vascular dysfunction in diabetes mellitus,9-13.
- Wei.M, Haffner.S.M, Effect of diabetes and level of ischemia on all causes and cardiovascular mortality, 1167-1172.
- Kannel.R, McGee.D.L, Diabetes and cardiovascular disease, Journal of the American Medical Association, 2035-2038.
- Meigs.J.B, Mittleman.M.A., Nathan.D.M, Singer.D.E, Hyperinsulinemia, hyperglycemia and impaired hemostasis. Journal of the American Medical Associations, 221-228.